Mode
Text Size
Log in / Sign up
N/A Completed N=10,117

All-Case Surveillance of Ofev in Patients With IPF in Japan

Source: ClinicalTrials.gov NCT02607722 ↗
Enrolled (actual)
10,117
Serious AEs
40.6%
Results posted
Oct 2024
Primary outcomePrimary: Number of Patients With Any Suspected Adverse Drug Reactions (ADRs) — 3852 Participants

Summary

This is a non-interventional study based on new data collection to gather real-world information (i.e., data under routine medical practice) on safety and effectiveness of the Ofev® Capsules treatment. The study will consist of a baseline visit and follow-up visits at Week 4, 13, 26, 39, 52, 65, 78, 91 and 104 for patients who have newly initiated Ofev® Capsules. The patients will be followed up until discontinuation of Ofev® Capsules treatment. As this is an observational study, no specific treatment is mandated or withheld from the patients. The choice of maintenance treatment for IPF must be according to regular medical practice and at the discretion of the physician (i.e., no randomised assignment of patient to treatment is performed). All patients administrated Ofev® Capsules after the launch at the sites contracted with the sponsor will be registered. The Case Report Forms (CRFs) of 1000 patients will be collected. However the patient registration continues until the approval condition has been removed. Patients participating in the subsequent follow-up will undergo regular observations. These observations should be reported after approximately Week 4, 13, 26, 39, 52, 65, 78, 91 and 104 since the initiation of Ofev® Capsules as long as they continue to receive the treatment. Patients will not be followed any longer once they are reported to have discontinued the Ofev® Capsules treatment.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Any Suspected Adverse Drug Reactions (ADRs)
3852
SECONDARY
Absolute Change From Baseline in Forced Vital Capacity (FVC) at Week 104
-152.5

Eligibility Criteria

Inclusion criteria

Essentially, patients are diagnosed with IPF based upon the most recent the American Thoracic Society (ATS), the European Respiratory Society (ERS), the Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) guideline.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02607722). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search